Vitexin 4′-glucoside is a leaf flavonoid for biological research
**Background**
Flavonoids are a diverse group of polyphenolic compounds widely distributed in plants, known for their significant biological activities, including antioxidant, anti-inflammatory, and antitumor properties. Among these, flavones serve as critical secondary metabolites that modulate various cellular signaling pathways. Research into plant-derived flavonoids is essential for discovering new therapeutic agents that can combat oxidative stress and cellular apoptosis. In particular, the genus Briza has been identified as a source of unique flavonoid variations that may offer insights into plant chemistry and pharmacology. In this context, we will introduce a leaf flavonoid identified from Briza stricta – Vitexin 4′-glucoside.
**Definition**
Vitexin 4′-glucoside is a polyphenolic flavone glycoside with the molecular formula C27H30O15 and a molecular weight of 594.52. According to the Vitexin 4′-glucoside description, it is a natural compound classified under the structural categories of flavonoids, flavones, and phenols.
**In Vitro Studies**
The Vitexin 4′-glucoside biological activity has been explored in the context of cellular health and oxidative stress. In vitro studies have investigated the effects of Vitexin 4′-glucoside alongside vitexin-2″-O-rhamnoside on human adipose-derived stem cells (hASCs). These studies focused on the compound’s ability to modulate growth and protect cells against oxidative stress-induced apoptosis. By analyzing the Vitexin 4′-glucoside in vitro data, researchers have evaluated how this flavonoid influences cell viability and the mechanisms of programmed cell death under stress conditions. Such findings suggest that this compound may play a role in maintaining stem cell homeostasis and protecting against oxidative damage. In conclusion, Vitexin 4′-glucoside is a natural flavonoid with potential applications in studying oxidative stress and cell survival.
Keywords
Vitexin 4′-glucoside, 38950-94-6, 4′-O-Glucosylvitexin, Others, Inhibitor, inhibitor, inhibit
References
[1] Wei W, et al. Effects of vitexin-2″-O-rhamnoside and vitexin-4″-O-glucoside on growth and oxidative stress-induced cell apoptosis of human adipose-derived stem cells. J Pharm Pharmacol. 2014;66(7):988-997.
[2] Christine A, et al. Flavonoid variation in the genus briza. Phytochemistry. Volume 11, Issue 8, August 1972, Pages 2507-2512.
**Background**
The polymerase chain reaction (PCR) has revolutionized molecular biology by allowing the exponential amplification of specific DNA sequences. Central to this process is the requirement for a DNA polymerase that can withstand the high temperatures necessary for DNA denaturation. Thermostable polymerases, derived from thermophilic organisms, are essential for this cycle, enabling the precise replication of genetic material for applications ranging from genetic diagnostics to forensic analysis. In the context of modern biotechnology, enhancing the robustness of these enzymes to handle complex templates, such as those found in clinical samples, is of significant research importance. Therefore, we will introduce a modified thermostable enzyme – Taq DNA polymerase.
**Definition**
Taq DNA polymerase is a thermostable DNA polymerase with an enzyme activity of ≥50 U/μL, where one unit is defined as the amount of enzyme that catalyzes the incorporation of 1 nmol AMP into the polynucleotide at 37°C in 60 min.
**In Vitro Studies**
According to the Taq DNA polymerase description, this product is produced by modifying the protein molecule of wild-type Taq DNA polymerase and expressing it in E. coli to enhance the enzyme’s anti-interference ability. The Taq DNA polymerase in vitro performance is particularly effective for PCR amplification directly from whole blood. Following the Taq DNA polymerase protocol, a typical 25 μL reaction system consists of 2.5 μL reaction buffer (100 mM Tris, 500 mM KCl, 15 mM MgCl2, 0.8% NP-40, pH 8.8), up to 5 μL whole blood DNA template, 2.5 μL 2.5 mM dNTP, 1 μL each of upstream and downstream primers (10 μM), and 0.5 μL Taq DNA polymerase. The thermal cycling conditions include an initial denaturation at 95°C for 3 min, followed by 35-40 cycles of 94°C for 30 sec, 55°C for 30 sec, and 72°C for 45-90 sec, with a final extension at 72°C for 7 min. In conclusion, Taq DNA polymerase is a highly stable and modified enzyme suitable for the amplification of DNA from challenging biological samples.
Keywords
Taq DNA polymerase, 2304873-37-6, DNA/RNA Synthesis, Inhibitor, inhibitor, inhibit
References
**Background**
The interaction between peptides and biological membranes is a fundamental process in cellular biology and pathogenesis. Many bacteria secrete specialized peptides that can disrupt the integrity of host cell membranes to facilitate infection or nutrient acquisition. Among these, hemolytic peptides produced by Staphylococcus species are of particular interest due to their ability to perturb lipid bilayers. Understanding the mechanisms by which these peptides interact with membranes provides critical insights into bacterial virulence and the development of membrane-targeted therapeutics. In this context, we will introduce a model membrane-interacting peptide – Delta-hemolysin.
**Definition**
Delta-hemolysin (also known as Delta-lysin) is a 26 amino acid hemolytic peptide produced by Staphylococcus with a molecular weight of 3006.51 and a specific Delta-hemolysin Formula of C137H225N33O40S.
**Biological Activity**
According to the Delta-hemolysin description, this peptide consists of the sequence {Formyl}-MAQDIISTIGDLVKWIIDTVNKFTKK. In terms of Delta-hemolysin biological activity, the peptide acts by perturbing the cellular membrane, which can lead to cell lysis. Because of these properties, it serves as a primary model in the study of peptides interacting with membranes. While it is highly effective at disrupting membranes, research indicates that Delta-hemolysin is poorly active against bacteria. Researchers seeking detailed Delta-hemolysin technical information can utilize this peptide to investigate the biophysical properties of membrane pore formation and the dynamics of peptide-lipid interactions. In conclusion, Delta-hemolysin is a potent hemolytic peptide and a valuable tool for membrane research.
Keywords
Delta-hemolysin, 74838-20-3, Delta-lysin, Bacterial, Hemolytic, Staphylococcus, cell lysis, membranes, bacteria, Inhibitor, inhibitor, inhibit
References
**Background**
Inflammation is a complex biological response involving the release of pro-inflammatory cytokines and the activation of key signaling pathways, such as NF-κB and ERK1/2. Excessive activation of these pathways can lead to endothelial hyperpermeability and tissue damage. Simultaneously, thyroid hormones play a critical role in the maturation of the central nervous system, and their deficiency can lead to significant neurological defects. Understanding the modulation of these inflammatory and endocrine pathways is essential for developing treatments for systemic inflammation and studying neurodevelopmental disorders. In this context, we will introduce an antithyroid agent with anti-inflammatory properties – Methylthiouracil.
**Definition**
Methylthiouracil is an antithyroid agent that targets NF-κB, ERK1, ERK2, and IL-6 to suppress inflammatory responses.
**In Vitro and In Vivo Studies**
According to the Methylthiouracil description, this compound suppresses the production of TNF-α and IL-6, while inhibiting the activation of NF-κB and ERK1/2. In Methylthiouracil in vitro studies, HUVECs were treated with various concentrations of the compound (0-20 μM) for 6 h following LPS (100 ng/mL) stimulation for 4 h. The results demonstrated that Methylthiouracil inhibits LPS-mediated hyperpermeability in endothelial cells, with optimal effects observed at concentrations above 5 μM. Immunofluorescence staining of F-actin revealed that post-treatment with 10 or 20 μM of the agent inhibited the formation of LPS-induced paracellular gaps, promoting the formation of dense F-actin rings. Furthermore, cellular viability assays indicated that concentrations up to 20 μM do not affect HUVEC viability over 24 h.
Regarding Methylthiouracil In Vivo activity, the compound significantly inhibits LPS-induced peritoneal dye leakage. In mouse models, subcutaneous injections of 142 or 284 μg/kg resulted in maximum peripheral blood dye concentrations of 10 or 20 μM, respectively. In dairy cows, oral administration leads to rapid appearance in plasma, urine, and milk, with selective accumulation in the thyroid gland. Additionally, Methylthiouracil can be used to model neurological defects by inducing thyroid deficiency. Following a specific Methylthiouracil protocol in rats, subcutaneous administration of a 4% suspension in 2% sodium alginate (0.05 mL from days 0-10; 0.1 mL from days 10-20; 0.2 mL from days 20-24) resulted in decreased body weight, reduced brain weight, and diminished responsiveness to external stimuli. Histological analysis of the cerebral cortex showed a decrease in pyramidal cell volume and a reduction in the intercellular matrix between neurons. In conclusion, Methylthiouracil is a versatile agent effective for both anti-inflammatory research and the induction of thyroid-deficiency-related neurological models.
Keywords
Methylthiouracil, 56-04-2, MTU, NF-κB, TNF Receptor, Interleukin Related, ERK, Nuclear factor-κB, Nuclear factor-kappaB, Tumor Necrosis Factor Receptor, TNFR, IL, Extracellular signal regulated kinases, Inhibitor, inhibitor
References
[1] Ku SK, et al. Anti-inflammatory effects of methylthiouracil in vitro and in vivo. Toxicol Appl Pharmacol. 2015 Nov 1;288(3):374-86.
[2] Heeremans A, et al. Elimination profile of methylthiouracil in cows after oral administration. Analyst. 1998 Dec;123(12):2629-32.
[3] EAYRS JT, et al. The effect of thyroid deficiency induced by methyl thiouracil on the maturation of the central nervous system. J Anat. 1951 Oct;85(4):350-8.
[4] Coda AR, et al. In vivo imaging of CNS microglial activation/macrophage infiltration with combined [18F]DPA-714-PET and SPIO-MRI in a mouse model of relapsing remitting experimental autoimmune encephalomyelitis. Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):40-52.
[5] Hofstetter HH, et al. Kinetics and organ distribution of IL-17-producing CD4 cells in proteolipid protein 139-151 peptide-induced experimental autoimmune encephalomyelitis of SJL mice. J Immunol. 2007 Feb 1;178(3):1372-8.
**Background**
Inflammatory diseases, including dermatological conditions, uveitis, and diabetic macular edema, are often characterized by the breakdown of biological barriers and the overproduction of pro-inflammatory cytokines. In the eye, the blood-retinal barrier is critical for maintaining homeostasis; its disruption leads to edema and vision loss. Glucocorticoids are widely used to manage these conditions due to their ability to suppress immune responses and stabilize endothelial junctions. Specifically, targeting the glucocorticoid receptor can inhibit the vascular endothelial growth factor (VEGF) pathway and reduce inflammatory signaling. In this context, we will introduce a potent steroid with highly selective glucocorticoid receptor agonist activity – Fluocinolone.
**Definition**
Fluocinolone is a potent glucocorticoid receptor agonist with the molecular formula C21H26F2O6. It is characterized by high lipophilicity, which allows for long-term sustained release when administered to tissues such as the vitreous.
**In Vitro and In Vivo Studies**
The Fluocinolone biological activity is primarily characterized by its ability to stabilize the blood-retinal barrier by enhancing endothelial tight junctions and inhibiting inflammatory factors. According to Fluocinolone technical information, its derivative, Fluocinolone acetonide, has demonstrated significant efficacy in various models. Fluocinolone in vitro studies indicate that Fluocinolone acetonide enhances endothelial tight junction activity while suppressing VEGF expression and inflammatory cytokine signaling within retinal endothelial cells.
Fluocinolone In Vivo research has further validated its therapeutic potential. In rat models, the derivative Fluocinolone acetonide (0.1-1.0 mg/kg; s.c.; once daily for 3-7 days) was found to reduce serum and adrenal corticosterone levels. In models of severe uveitis, the use of a sustained delivery device (2 mg/15 mg; intravitreal implantation for 5-19 months) successfully suppressed ocular inflammation and improved visual acuity. Furthermore, in rabbit models, an intravitreal implant providing 0.2 μg/day for 36 months maintained stable intraocular drug levels with undetectable systemic exposure. In conclusion, Fluocinolone is a highly lipophilic and potent steroid that serves as an effective tool for research into diabetic macular edema, uveitis, and other inflammatory diseases.
Keywords
Fluocinolone, 807-38-5, Glucocorticoid Receptor, Inhibitor, inhibitor, inhibit
References